PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: PIPELINE LANDSCAPE PART 08: MARKET SEGMENTATION BY PRODUCT • Segmentation by product • Comparison by product • C1 inhibitors – Market size and forecast 2017-2022 • Icatibant – Market size and forecast 2017-2022 • Ecallantide – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by product PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Innovative treatment strategies • Improved route of administration products • Development of monoclonal antibody PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • BioCryst Pharmaceuticals • Cipla • CSL • Pharming Group • Shire PART 16: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global rare disease market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Pipeline landscape by development phase Exhibit 19: Key clinical trial candidates of hereditary angioedema Exhibit 20: Product – Market share 2017-2022 (%) Exhibit 21: Comparison by product Exhibit 22: C1 inhibitors – Market size and forecast 2017-2022 ($ mn) Exhibit 23: C1 inhibitors – Year-over-year growth 2018-2022 (%) Exhibit 24: Icatibant – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Icatibant – Year-over-year growth 2018-2022 (%) Exhibit 26: Ecallantide – Market size and forecast 2017-2022 ($ mn) Exhibit 27: Ecallantide – Year-over-year growth 2018-2022 (%) Exhibit 28: Others – Market size and forecast 2017-2022 ($ mn) Exhibit 29: Others – Year-over-year growth 2018-2022 (%) Exhibit 30: Market opportunity by product Exhibit 31: Customer landscape Exhibit 32: Global – Market share by geography 2017-2022 (%) Exhibit 33: Regional comparison Exhibit 34: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 35: Americas – Year-over-year growth 2018-2022 (%) Exhibit 36: Top three countries in Americas Exhibit 37: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 38: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 39: Top three countries in EMEA Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 41: APAC – Year-over-year growth 2018-2022 (%) Exhibit 42: Top three countries in APAC Exhibit 43: Market opportunity Exhibit 44: Vendor landscape Exhibit 45: Landscape disruption Exhibit 46: Vendors covered Exhibit 47: Vendor classification Exhibit 48: Market positioning of vendors Exhibit 49: BioCryst Pharmaceuticals: Overview Exhibit 50: BioCryst Pharmaceuticals: Organizational developments Exhibit 51: BioCryst Pharmaceuticals: Key offerings Exhibit 52: BioCryst Pharmaceuticals: Key customers Exhibit 53: Cipla – Overview Exhibit 54: Cipla – Business segments Exhibit 55: Cipla – Organizational developments Exhibit 56: Cipla – Geographic focus Exhibit 57: Cipla – Segment focus Exhibit 58: Cipla – Key offerings Exhibit 59: Cipla – Key customers Exhibit 60: CSL – Overview Exhibit 61: CSL – Business segments Exhibit 62: CSL – Organizational developments Exhibit 63: CSL – Geographic focus Exhibit 64: CSL – Segment focus Exhibit 65: CSL – Key offerings Exhibit 66: CSL – Key customers Exhibit 67: Pharming Group – Overview Exhibit 68: Pharming Group – Business segments Exhibit 69: Pharming Group – Organizational developments Exhibit 70: Pharming Group – Geographic focus Exhibit 71: Pharming Group – Key offerings Exhibit 72: Pharming Group – Key customers Exhibit 73: Shire – Overview Exhibit 74: Shire – Business segments Exhibit 75: Shire – Organizational developments Exhibit 76: Shire – Geographic focus Exhibit 77: Shire – Segment focus Exhibit 78: Shire – Key offerings Exhibit 79: Shire – Key customers   

BioCryst Pharmaceuticals Cipla CSL Pharming Group Shire